pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ultragenyx Pharmaceutical Inc. ($RARE) · news · pharmadog
← back to Ultragenyx Pharmaceutical Inc.
News mentioning $RARE
825
stories
18d
Trending: Top biopharma disciplines with jobs live now
biospace
18d
Deep dive: Psychedelics back on FDA’s doorstep
biospace
18d
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
biospace
18d
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
biospace
18d
Opinion: How my cancer diagnosis changed the way I train physicians
stat
19d
AI is changing the talent biotech companies compete to hire
biospace
19d
5 biotechs braving the commercial waters with product launches
biospace
19d
A fourth measles death is reported in Pennsylvania
stat
19d
FDA opens Operation TrialBlazer for applications, hoping to reshore early trials
biospace
19d
Rare disease reform, CMC risk, reshoring US trials top of mind ahead of PDUFA VIII meeting
biospace
20d
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
fiercebiotech
20d
Blood centers can help biopharma scale cell and gene therapies
biospace
20d
Judge blocks Trump administration plans to limit visa length for grad students, postdocs
stat
20d
FDA looks into reassessing criteria around rare disease trials, endpoint selection
endpoints
20d
Kennedy to deliver keynote for anti-vaccine group he once led
stat
20d
Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’
biospace
20d
Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand
biospace
20d
STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more
stat
20d
Scholar Rock SMA drug approved by FDA
biopharma dive
20d
Scholar Rock secures first FDA approval for muscle-targeting rare disease drug
biospace
20d
Scholar Rock gets FDA nod for spinal muscular atrophy drug
endpoints
20d
Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
fiercebiotech
20d
Opinion: Restoring public trust in science doesn’t have a simple solution. That’s OK
stat
21d
Psychedelic therapies ride wave of public favor into FDA hearing
biospace
21d
After a brief storm of political headwinds, mRNA is back with strong momentum
biospace
21d
Recon: New FDA oncology chief vows continued innovation in OCE; FDA approves drugs for two rare genetic diseases
raps
23d
STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
stat
23d
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
biopharma dive
23d
Disc sets up polycythemia vera challenge but Silence maintains lead
biospace
23d
Boycott launched against American Diabetes Association includes journal
stat
← prev
page 5 of 28
next →
